-
MyChart
Log in to our secure, personalized website to manage your care (formerly myMDAnderson).
- Donate Today
Immunotherapy has taken hold as an effective treatment for a variety of advanced cancers, but so far, colorectal cancer has stubbornly resisted.
However, research led by MD Anderson shows that resistance could be struck down. The recent international clinical trial helped expose a weak spot that leaves about 5% of colorectal tumors receptive to immune attack. (see the related story "5 years in, the Moon...
Immune cells that rush to repair damage caused by inflammatory tissue are subverted to cancer-promoting allies by pancreas cells that feature...
Fewer than 30% of the women in the U.S. with abnormal, benign lesions known as atypical hyperplasia (AH) and lobular carcinoma in situ (LCIS...
Despite the availability of vaccines that could prevent the majority of cancers caused by the human papillomavirus (HPV), the incidence of cervical, oropharyngeal, anal, vulvar and vaginal cancers is increasing in the United States.
MD Anderson’s HPV-Related Cancers Moon Shot™ is working to identify practical solutions and strategies to increase vaccination rates, improve screening and diagnostic options, and develop novel...
“Driving Innovative Cancer Science to Patient Care” was the theme of the American Association for Cancer Research’s annual meeting, which...
The American Association for Cancer Research (AACR) has selected Isaiah J. Fidler, D.V.M., Ph.D., professor of Cancer Biology, as recipient...
Melanoma cells are able to evade cancer immunotherapy by using a specific protein to hide from immune system T cells out to seek and destroy...
When people breathe, there’s movement inside their bodies.
Organs, tissues and even cancer patients’ tumors move around all the time...
MD Anderson was awarded $22.3 million from the Cancer Prevention and Research Institute of Texas (CPRIT), accounting for 30% of the $73.5...
MD Anderson’s Colorectal Cancer Moon Shot™ is committed to the prevention and early detection of the third most common cancer diagnosed in...